Shockwave Medical Q1 revenue up 36% to $218.8M, net income $55.3M; withdraws 2024 guidance due to JNJ acquisition

Shockwave Medical, Inc.

2024-Q1 EPS reported $1.44 revenue$218,805,000

Revenue $218.8M (+36% YoY); net income $55.3M ($1.44 diluted EPS) vs $39.1M ($1.01) in Q1 2023.
Gross margin 87%; operating expenses $148.2M (+48% YoY) on sales force expansion.
Adjusted EBITDA $68.5M, up 19% from $57.5M in Q1 2023.
Withdraws full-year 2024 guidance due to proposed Johnson & Johnson acquisition.
Cash, cash equivalents and short-term investments $1,029.2M as of March 31, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Shockwave Medical, Inc. reported first quarter ended March 31, 2024 results: revenue $218.8 million, net income $55.3 million, EPS $1.48 and $1.44.

Period: first quarter ended March 31, 2024
Revenue: $218.8 million
Net income: $55.3 million
EPS: $1.48 and $1.44
Result: reported results

Exact text from the filing

to bring our life-changing therapies to even more patients across the globe.” First Quarter 2024 Financial Results Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001171843-24-002571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.